NCT00905047 2026-03-13
COLOCROSS
Centre Oscar Lambret
Phase 3 Completed
Clinical Trials
15 trialsNCT07468630 2026-03-12
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT01918527 2026-03-10
Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer
Vejle Hospital
Phase 3 Active not recruiting
NCT05062889 2026-02-03
ERASE-CRC
Gruppo Oncologico del Nord-Ovest
Phase 2 Suspended
NCT05108428 2026-01-08
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT06686576 2025-12-18
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06124378 2025-09-24
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 2 Active not recruiting
NCT06368141 2025-09-24
NeoCHIC
Ruijin Hospital
Phase 2 Recruiting
NCT02978612 2025-09-05
ACE
Oslo University Hospital
Phase 2 Completed
NCT06490536 2025-08-29
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3 Recruiting
NCT07132008 2025-08-20
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 3 Not yet recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT06949111 2025-07-01
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT05870800 2025-05-25
NICER
Baylor College of Medicine
Phase 2 Recruiting
NCT04068103 2025-05-07
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NRG Oncology
Phase 2/3 Active not recruiting